Oculis Holding AG announced positive results from the phase 2 ACUITY trial investigating Privosegtor (OCS-05) in acute optic neuritis. The data was presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 Congress in Copenhagen.

Data from the ACUITY Phase 2 trial demonstrated Privosegtor's neuroprotective effects in patients with acute optic neuritis, including preservation of retinal structure and improvements in visual function. These findings align with preclinical studies in animal models of neuroinflammation and neurodegeneration, where Privosegtor preserved retinal ganglion cells and was associated with improvements in mobility and overall functional outcomes.

Privosegtor has received orphan drug designation from both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for acute optic neuritis. In addition to this indication, a neuroprotective treatment could potentially have wide applicability in neuro-ophthalmic and neurology indications, the company said. RP RP